HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Supplement Office Late, Tighter Regulation Overdue – Durbin, Blumenthal

This article was originally published in The Tan Sheet

Executive Summary

No member of Congress objects to FDA establishing an Office of Dietary Supplement Programs, but Sens. Blumenthal and Durbin plan to introduce legislation for stronger oversight of the industry. FDA says the office will raise the profile of supplement market enforcement within the agency.

You may also be interested in...



Senate Proponents For Tighter Supplement Industry Regulation Question FDA’s Food Programs Overhaul

“We are concerned that these changes could divert resources, funding, and attention from the supplement market at a time when it is needed more than ever,” Democrats Dick Durbin and Richard Blumenthal says in letter to FDA.

Durbin Lights Supplement MPL Flare In US Senate

Senate votes down Illinois Democrat’s proposal to amend stopgap appropriations bill with language calling for establishing mandatory products listing program in FDA. But proposal to give FDA MPL authority likely will return in Congress, says Natural Products Association.

Sen. Durbin Will Introduce US Mandatory Supplement Registration Bill

Sen. Durbin has been a critic of FDA’s regulation of VMS product market regulation, putting him at odds with industry stakeholders. But “Dietary Supplement Listing Act” he and Sen. Braun will introduce later in week has support of CHPA and CRN.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel